Inventiva (NASDAQ:IVA) Stock Gets Price Target Bump from Truist Financial

Inventiva (NASDAQ:IVA) had its price objective boosted by equities research analysts at Truist Financial from $13.00 to $18.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 409.05% from the company’s current price.

Several other equities research analysts also recently weighed in on IVA. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Guggenheim upped their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Finally, Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.86.

Inventiva Stock Performance

Shares of NASDAQ:IVA traded up $0.08 during trading on Friday, hitting $3.54. 1,547,517 shares of the company’s stock were exchanged, compared to its average volume of 842,853. Inventiva has a 52-week low of $3.11 and a 52-week high of $7.98. The business’s 50-day simple moving average is $4.34 and its 200 day simple moving average is $4.67.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The business had revenue of $0.75 million during the quarter. Equities research analysts forecast that Inventiva will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

A number of large investors have recently added to or reduced their stakes in the company. NEXTBio Capital Management LP acquired a new position in Inventiva during the 4th quarter valued at approximately $6,039,000. Propel Bio Management LLC acquired a new position in shares of Inventiva in the 4th quarter valued at about $4,650,000. Eventide Asset Management LLC purchased a new stake in Inventiva in the 4th quarter worth approximately $1,155,000. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva during the 1st quarter worth approximately $1,111,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Inventiva during the 4th quarter valued at approximately $603,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.